CVS Health's (CVS) CVS Caremark unit has agreed to include Zydus Lifesciences' diabetes medications, Zituvio, Zituvimet, and Zituvimet XR in its template formulary, effective Jan. 1.
Approved by the US Food and Drug Administration through the 505(b)(2) pathway, the medications containing sitagliptin and metformin hydrochloride help improve glycemic control in adults with type 2 diabetes mellitus, Zydus Lifesciences said Tuesday.
Price: 45.96, Change: +0.13, Percent Change: +0.29
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.